The Explore covid-19 project was born from combining the forces of Marseille Immunopôle. It should lead us to better understand this new disease and improve the prognosis of our patients.
After my medical studies in Saint-Etienne, I came to Marseille to do my residency in internal medicine. Although I have now turned towards intensive care, I have kept my taste for the multidisciplinary approach of internists, which led me to deepen my knowledge of immunology in Eric Vivier’s laboratory.
I am now particularly interested in the innate immune response and hyper-inflammation found in certain serious pathologies such as sepsis or macrophage activation syndrome, a rare disease where the macrophages and T lymphocytes that normally protect us expand uncontrollably and destroy healthy blood cells.
Covid-19 patients in respiratory distress that we receive at the intensive care unit are also victims of an “immune storm”. There is still no effective treatment for these patients, which is why I decided to get involved in Explore Covid-19, a project in which Marseille Immunopôle, the AP-HM and the Lavéran Hospital, and the immunotherapy specialist Innate Pharma have joined their forces at the frontline against covid-19 to explore the immune component of the disease and identify new therapeutic avenues. Specifically, we wish to answer 2 questions: what are the immune mechanisms involved in the severe forms of the disease? Can this mechanism be effectively modulated to calm the immune system’s runaway?
Helping patients on a daily basis while trying to identify the biological origins of their disease and new ways to fight it, that’s exactly why I do this job!#clinique
The Pioneer Project draws on the collaborative environment of Marseille Immunopôle, which brings together clinicians, academics and industry players committed to the benefit of patients
This is the DNA of the cluster to feed local excellence, including, of course, fundamental and applied immunology, and to support the emergence of sector initiatives with strong potential.
Each year, a large number of clinical trials are conducted by APHM clinicians alone or in partnership with industry players in biopharmaceuticals.
AMU, AP-HM, CIML
Immunotherapy is expanding to other cancers types: kidney cancer, bladder cancer, hepatocellular carcinoma, Hodgkin’s lymphoma, non-Hodgkin’s lymphoma… but we are still only at the beginning of the story!